DPP4 and diabetes mellitus: DPP‐4 inhibitors are among the important therapeutic classes of DM drugs, and several such inhibitors, such as sitagliptin, saxagliptin, linagliptin, and alogliptin, have been approved by the FDA and are available on the market (Pawaskar et al. 2019; Wu et al. 2016).